• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Elekta

51.25 SEK

+0.99 %

Less than 1K followers

EKTA B

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.99 %
-2.66 %
-5.88 %
-9.69 %
-9.69 %
+4.42 %
-38.50 %
-58.74 %
+487.49 %

Elekta operates in the medical technology industry and focuses on the development, manufacture and distribution of medical equipment for cancer treatment and neurosurgery. The company's products include radiotherapy machines and diagnostic imaging systems. The business has a global market position. Elekta was founded in 1972 and is headquartered in Stockholm.

Read more
Market cap
19.66B SEK
Turnover
16.14M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27.8.
2026

Interim report Q1'27

3.9.
2026

General meeting '26

4.9.
2026

Half year dividend

Regulatory press release17.06.2026 klo 10.30

Elekta presents financial targets and detailed outlook ahead of Capital Markets Day

Elekta
Press release12.06.2026 klo 08.30

Nomination Committee’s proposal for the Board of Directors prior to Elekta’s Annual General Meeting 2026

Elekta
Regulatory press release28.05.2026 klo 08.30

Year-end report May–April 2025/26

Elekta

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release18.05.2026 klo 08.30

New research presented at ESTRO 2026 highlights advances in MR-guided radiotherapy

Elekta
Press release13.05.2026 klo 08.30

Invitation to the presentation of Elekta’s fiscal year 2025/26

Elekta
Press release17.04.2026 klo 08.00

Invitation to Elekta's Capital Markets Day on June 17, 2026

Elekta
Regulatory press release05.03.2026 klo 08.30

Third quarter, November–January 2025/26

Elekta
Regulatory press release25.02.2026 klo 08.30

Change in Elekta’s Nomination Committee for the Annual General Meeting 2026

Elekta
Press release19.02.2026 klo 08.30

Invitation to Elekta’s Q3 2025/26 call at 9:00 a.m. CET, March 5

Elekta
Press release30.01.2026 klo 13.00

Elekta presents Strategic Update: growth, innovation, and operations

Elekta
Press release23.01.2026 klo 12.10

Elekta appoints Tomas Eliasson as Vice Chair of the Board

Elekta
Regulatory press release16.01.2026 klo 10.54

Elekta receives FDA 510(k) clearance for Elekta Evo linear accelerator

Elekta
Press release12.01.2026 klo 11.00

Invitation to Elekta's Strategic Update event on January 30

Elekta
Regulatory press release26.11.2025 klo 08.30

Second quarter, August–October 2025/26

Elekta
Press release12.11.2025 klo 08.30

Invitation to the presentation of Elekta’s second quarter 2025/26

Elekta
Regulatory press release31.10.2025 klo 08.30

Elekta’s Nomination Committee for the Annual General Meeting 2026

Elekta
Press release09.10.2025 klo 08.30

New impact report reveals radiotherapy’s role in cancer care

Elekta
Press release29.09.2025 klo 21.10

Study shows MRI-guided adaptive radiotherapy with Elekta Unity improves patient-reported urinary symptoms in men with prostate cancer

Elekta
Press release25.09.2025 klo 08.30

Elekta marks two millionth patient treated with Leksell Gamma Knife radiosurgery

Elekta
Regulatory press release08.09.2025 klo 08.30

Elekta announces changes in Executive Management

Elekta